Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction

clinical trial

Details

Instance of: clinical trial
Start time: September 2012
End time: February 2013
Country: United States
Main subject: hepatitis, hepatitis C, hepatitis A, hepatitis B
clinical trial phase: phase I clinical trial
maximum age: 75
minimum age: 18
number of participants: 43
research site: Orlando Clinical Research Center
short name: PK
sponsor: Bristol-Myers Squibb
study type: interventional study
title: An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction

Nothing in the MetaHistoryBook collection references this item yet.